第一美卡成立於1992年03月,產量為全球前十大,亞洲第二大,全台第一大之晶片卡廠,同時第一美卡擁有台灣最先進之製卡設備及優秀的專業人才,以一貫高品質的產品深耕各式卡片的技術開發,並致力於不斷的改良及創新各式高端精密卡片。
本公司座落於桃園市蘆竹區,為目前全國製卡設備最完整之工廠,自廠內有各式高規格之印刷機、密碼機、植晶機及全球最大產能之芯片入碼機,再配合自動化的包裝設備,具備彈性的產能規劃優勢,以最具競爭力之成本,在最短時間內提供客戶高品質的產品與服務。全廠一貫的作業方式,不但可確保產品質量,並在出貨速度上保有市場先機,這就是我們對質量的堅持與自我要求。獲得 ISO 9001 /ISO14000/ ISO 27001/ ISO 18000/VISA/Master/JCB/銀聯/SAS/CQM...等多項認證,以其高品質、高效率及合理的價格獲得廣大客戶的肯定與認同。
第一美卡的卡片生產線,均採全自動化一貫生產,全程並經過周密的質量管理與產品檢測。包括嚴格的拍照檢測、利用各種先進的儀器及設備來測試卡片。此外,更不斷針對製程進行改善以提高效率與產能、降低生產成本,才能提供客戶更實時、更具競爭力的產品與服務,進而達到與客戶共創利潤的雙贏局面。
育世博為楊育民博士及蕭世嘉博士在2017年共同創立。董事長楊育民博士曾在Genentech、Juno Therapeutics等大藥廠擔任執行副總裁,具數十年跨國藥廠管理經驗。執行長蕭世嘉博士為青年創業家,其核心技術——抗體細胞連結(Antibody-Cell Conjugation,ACC),衍生自2022年諾貝爾化學獎得主、美國史丹佛大學Carolyn Bertozzi教授的點擊化學(click chemistry)生物正交化學(bioorthogonal chemistry)研究,其也為此技術的共同發明人之一。
育世博專注研發新世代的細胞免疫療法,針對實體腫瘤及血液腫瘤等未滿足醫療需求,應用ACC 技術平台,發展出一系列「異體」的抗體連結免疫細胞 (Antibody-Conjugated Effector cells, ACE) 產品,且產品因「可凍存」,故同時具備「現成型 (off-the-shelf)」之優勢。除上述ACC技術平台業已獲得多國專利外,育世博自行開發出具有CD16表面抗原表現,且對腫瘤細胞有較強毒殺能力的自然殺手細胞oNK,亦已取得PCT專利。目前育世博同步也完成另一個細胞平台gamma delta T 細胞的開發,透過ACC 技術平台,發展出接續的產品,對於腫瘤的毒發發揮絕佳的效果。
目前公司已有多項細胞治療新藥進入臨床階段:首件自然殺手細胞治療新藥ACE1702,目標適應症為HER2表現實體腫瘤; 接續的ACE1831與ACE2016,係針對CD20表現血液腫瘤與EGFR表現實體腫瘤之gamma delta T細胞新藥,皆於台灣與美國同步進行一期臨床試驗,公司也籌畫將細胞新藥應用於自體免疫疾病上的治療。
Acepodia was founded in 2017 by Dr. Patrick Y. Yang, former EVP of Juno Therapeutics, Roche, and Genentech, and by Dr. Sonny Hsiao, UC Berkeley Cell Biologist and one of the inventors of Acepodia’s core technology, which is derived from the research on click chemistry and bioorthogonal chemistry by the 2022 Nobel Prize winner in Chemistry, Professor Carolyn Bertozzi of Stanford University. Dr. Hsiao is also one of the co-inventors of this technology. Acepodia is a pubilc biotechnology company focused on developing novel, targeted, allogeneic cell therapies to treat cancers. Acepodia is employing a flexible therapeutic design that leverages cutting-edge technologies to develop the next generation of off-the-shelf cell therapies by supercharging select oNK cells and gamma delta (γδ) T cells to target and engage cancer cells. Our approach is based on developing the most potent immune cells possible and equipping them with the optimal cellular targeting mechanisms needed to engage cancer cells with proprietary platform technologies. By arming our powerful cancer-killing cells with our tumor-targeting technology, Antibody-Cell Conjugation (ACC), Acepodia believes it can develop powerful, accessible cell therapies for patients with cancer.
Acepodia has already advanced several cell therapy candidate programs into the clinical stage: The first is ACE1702, , a HER2-targeting NK cell therapy candidate. Following that are ACE1831 and ACE2016, gamma delta T cell therapies aimed at CD20-expressing hematological tumors and EGFR-expressing solid tumors, respectively. These drugs are undergoing Phase I clinical trials simultaneously in Taiwan and the United States. The company is also expanding the application of cell therapy drugs to the treatment of autoimmune diseases and is currently planning to apply for a Phase I clinical trial with the U.S. FDA.